KR102735275B1 - 바이러스성 색전술을 위한 조성물 및 방법 - Google Patents

바이러스성 색전술을 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102735275B1
KR102735275B1 KR1020187001688A KR20187001688A KR102735275B1 KR 102735275 B1 KR102735275 B1 KR 102735275B1 KR 1020187001688 A KR1020187001688 A KR 1020187001688A KR 20187001688 A KR20187001688 A KR 20187001688A KR 102735275 B1 KR102735275 B1 KR 102735275B1
Authority
KR
South Korea
Prior art keywords
virus
tumor
oncolytic
composition
embolization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187001688A
Other languages
English (en)
Korean (ko)
Other versions
KR20180021083A (ko
Inventor
황태호
이남희
조몽
전웅배
변두진
Original Assignee
신라젠(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신라젠(주) filed Critical 신라젠(주)
Publication of KR20180021083A publication Critical patent/KR20180021083A/ko
Application granted granted Critical
Publication of KR102735275B1 publication Critical patent/KR102735275B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020187001688A 2015-06-19 2016-06-17 바이러스성 색전술을 위한 조성물 및 방법 Active KR102735275B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182383P 2015-06-19 2015-06-19
US62/182,383 2015-06-19
PCT/IB2016/000993 WO2017037523A1 (en) 2015-06-19 2016-06-17 Compositions and methods for viral embolization

Publications (2)

Publication Number Publication Date
KR20180021083A KR20180021083A (ko) 2018-02-28
KR102735275B1 true KR102735275B1 (ko) 2024-11-29

Family

ID=58186857

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187001688A Active KR102735275B1 (ko) 2015-06-19 2016-06-17 바이러스성 색전술을 위한 조성물 및 방법

Country Status (8)

Country Link
US (1) US10517910B2 (enExample)
EP (1) EP3310383B1 (enExample)
JP (1) JP6827467B2 (enExample)
KR (1) KR102735275B1 (enExample)
CN (1) CN108025056B (enExample)
AU (1) AU2016313969B2 (enExample)
ES (1) ES2795010T3 (enExample)
WO (1) WO2017037523A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
AU2016313969B2 (en) 2015-06-19 2021-12-23 Sillajen, Inc. Compositions and methods for viral embolization
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
WO2017147554A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
CA3031416C (en) * 2016-07-21 2023-09-19 Kolon Life Science, Inc. Recombinant vaccinia virus and use thereof
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
CN109554353B (zh) * 2017-09-26 2021-08-06 杭州康万达医药科技有限公司 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
KR20190059421A (ko) * 2017-11-23 2019-05-31 주식회사 바이오녹스 항암바이러스의 간동맥 투여를 이용한 간암 치료방법
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
CA3112654A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
US20240024393A1 (en) * 2019-01-25 2024-01-25 Virocure, Inc. Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus
US11685904B2 (en) 2019-02-14 2023-06-27 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
CN114615988A (zh) * 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台
DE102020101197A1 (de) * 2020-01-20 2021-07-22 Charité - Universitätsmedizin Berlin Medizinprodukt zur Arzneimittelabgabe mit verstärkter Wirkung
KR20230038496A (ko) 2020-07-13 2023-03-20 트랜스진 면역 억제의 치료
CN114681393A (zh) * 2020-12-25 2022-07-01 上海三维生物技术有限公司 溶瘤腺病毒的栓塞剂
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CN116942888B (zh) * 2023-09-11 2026-03-24 科睿驰（深圳）医疗科技发展有限公司 淀粉水凝胶栓塞微球及其制备方法
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211165A1 (en) * 2000-03-24 2003-11-13 Jean-Marie Vogel Microspheres for active embolization
US8980246B2 (en) * 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
AU683211B2 (en) 1992-04-08 1997-11-06 United States of America as represented by The Secretary Department of Health and Human Services, The Wild-type measles virus glycoproteins: vaccine and detection method therefor
FR2736358B1 (fr) 1995-07-05 1997-09-26 Agronomique Inst Nat Rech Virus myxomateux recombinant
AU8877098A (en) 1997-09-05 1999-03-29 Nycomed Imaging As Polymer particles made of polyvinyl alcohol and comprising contrast agent for chemoembolization
FR2784580B1 (fr) * 1998-10-16 2004-06-25 Biosepra Inc Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
JP2004510723A (ja) * 2000-10-06 2004-04-08 ヤゴテック　アーゲー 低下した分子量のアミロペクチンをベースとする精製された澱粉を含む制御放出投与のための生物分解性微粒子
NZ536102A (en) 2002-05-09 2008-01-31 Oncolytics Biotech Inc Oncolytic viruses, in particular reovirus, for reducing pain associated with proliferative disorders, particularly with the growth of a solid tumour mass
WO2004014314A2 (en) * 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
EP1933857A2 (en) * 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
EP2116256A1 (en) * 2007-03-01 2009-11-11 Cosmed Pharmaceutical Co., Ltd. Transdermal immune preparation, method for production of the same, and transdermal immunization method using the same
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
KR101838472B1 (ko) * 2009-09-14 2018-03-15 신라젠(주) 종양 용해 백시니아 바이러스 병용 암 치료요법
WO2011135734A1 (ja) * 2010-04-28 2011-11-03 株式会社アルファ・ナノ・メディカ ウイルスの複合体、それを含有する治療薬及び治療方法
ES2542242T3 (es) * 2010-11-29 2015-08-03 Centre Hospitalier Universitaire Vaudois Composición de quimioembolización que comprende agentes antiangiogénicos
US9919047B2 (en) * 2011-01-04 2018-03-20 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
KR102022952B1 (ko) * 2011-08-05 2019-09-20 신라젠(주) 백시니아 바이러스의 생산을 위한 방법 및 조성물
US20140086976A1 (en) * 2012-08-20 2014-03-27 Aladar A. Szalay Compositions containing protein polymers and vaccinia virus, and methods of use thereof
US20140194370A1 (en) * 2013-01-08 2014-07-10 University Of Utah Research Foundation Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer
AU2016313969B2 (en) 2015-06-19 2021-12-23 Sillajen, Inc. Compositions and methods for viral embolization
HK1255192A1 (zh) * 2015-09-08 2019-08-09 Sillajen, Inc. 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211165A1 (en) * 2000-03-24 2003-11-13 Jean-Marie Vogel Microspheres for active embolization
US8980246B2 (en) * 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEPATOLOGY, Vol. 48, No. 6, 2008*

Also Published As

Publication number Publication date
AU2016313969B2 (en) 2021-12-23
ES2795010T3 (es) 2020-11-20
EP3310383A4 (en) 2019-02-27
JP6827467B2 (ja) 2021-02-10
EP3310383A1 (en) 2018-04-25
AU2016313969A1 (en) 2018-02-15
EP3310383B1 (en) 2020-02-19
HK1252004A1 (en) 2019-05-10
US10517910B2 (en) 2019-12-31
CN108025056B (zh) 2022-01-14
JP2018517778A (ja) 2018-07-05
KR20180021083A (ko) 2018-02-28
WO2017037523A1 (en) 2017-03-09
CA2990133A1 (en) 2017-03-09
US20180303886A1 (en) 2018-10-25
CN108025056A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
US10517910B2 (en) Compositions and methods for viral embolization
Wollmann et al. Oncolytic virus therapy of glioblastoma multiforme–concepts and candidates
US8227440B2 (en) Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US12319931B2 (en) Oncolytic virus expressing interferon and application therefor
CA2681096C (en) Oncolytic vaccinia virus cancer therapy
EP1121137B1 (en) Method for killing tumor and tumor associated endothelial cells using adenoviral mutants
Meerani et al. Oncolytic viruses in cancer therapy
CN101137748B (zh) 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
CA2990133C (en) Compositions and methods for viral embolization
Kirn Monthly Update: Oncologic, Endocrine & Metabolic: Replicating oncolytic viruses: An overview
HK1252004B (en) Compositions and methods for viral embolization
Saha et al. Viral oncolysis of glioblastoma
CN100451109C (zh) 重组1型单纯疱疹病毒及制备方法和应用
CN100379453C (zh) 粘液瘤病毒在治疗癌症和慢性病毒感染中的用途
Bell et al. HISTORY OF ONCOLYTIC VIRUSES
HK1081099B (en) Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000